The Results From This Immune Thrombocytopenia Trial are Good News for Patients
source: pixabay.com

The Results From This Immune Thrombocytopenia Trial are Good News for Patients

According to a story from ucb.com, the biopharmaceutical company UCB has recently released the final results from its phase 2 clinical trial which tested the company's investigational monoclonal antibody rozanolixizumab…

Continue Reading The Results From This Immune Thrombocytopenia Trial are Good News for Patients
A Recent Trial Found the Drug Rinvoq Can be Effective Treatment for Ankylosing Spondylitis
source: pixabay.com

A Recent Trial Found the Drug Rinvoq Can be Effective Treatment for Ankylosing Spondylitis

According to a story from Ankylosing Spondylitis News, the results of a recent phase 2/3 clinical trial indicate that the drug upadacitinib (marketed as Rinvoq) can be an effective treatment…

Continue Reading A Recent Trial Found the Drug Rinvoq Can be Effective Treatment for Ankylosing Spondylitis
Lupus Nephritis Patients Should be Excited About the Results of This Phase 3 Trial
source: pixabay.com

Lupus Nephritis Patients Should be Excited About the Results of This Phase 3 Trial

According to a story from BioPortfolio, the biopharmaceutical company Aurinia Pharmaceuticals, Inc. has recently announced positive findings from its phase 3 clinical trial of the experimental drug voclosporin, which was…

Continue Reading Lupus Nephritis Patients Should be Excited About the Results of This Phase 3 Trial
FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes
source: pixabay.com

FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes

According to a story from BioPortfolio, Acceleron Pharma and the Bristol-Myers Squibb Company have announced recently that the US Food and Drug Administration (FDA) will review the supplemental Biologics License…

Continue Reading FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes
The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease
source: pixabay.com

The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease

According to a story from Business Wire, the biopharmaceutical company Bristol-Myers Squibb has recently announced that the US Food and Drug Administration (FDA) has granted the company's drug abatacept (marketed…

Continue Reading The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease
Study Finds Increased Risk of Bladder Problems for Primary Sjögren’s Syndrome Patients
source: pixabay.com

Study Finds Increased Risk of Bladder Problems for Primary Sjögren’s Syndrome Patients

A recent study published in the scientific journal PLOS One has determined that patients with the rare disorder primary Sjögren's syndrome are at a greater risk of bladder problems than previously thought.…

Continue Reading Study Finds Increased Risk of Bladder Problems for Primary Sjögren’s Syndrome Patients
XLA: This Father Helped Identify the Disease That Killed His First-Born Son—and Saved His Youngest in the Process
source: pixabay.com

XLA: This Father Helped Identify the Disease That Killed His First-Born Son—and Saved His Youngest in the Process

According to a story from USA Today, Thanksgiving 2009 was a harrowing time for the Anderson family. About a month earlier, Darrin and Sarah Anderson's oldest son Henry had died…

Continue Reading XLA: This Father Helped Identify the Disease That Killed His First-Born Son—and Saved His Youngest in the Process
First Patient Dosed with Experimental Treatment for Multiple Myeloma in Clinical Trial
source: pixabay.com

First Patient Dosed with Experimental Treatment for Multiple Myeloma in Clinical Trial

According to a story from Myeloma Research News, the first patient has been dosed with an experimental allogeneic (donor derived) CAR-T cell therapy called UCARTCS1 as part of a phase…

Continue Reading First Patient Dosed with Experimental Treatment for Multiple Myeloma in Clinical Trial
Study Reveals a Key Difference Between People of Color with Multiple Sclerosis and Whites
source: pixabay.com

Study Reveals a Key Difference Between People of Color with Multiple Sclerosis and Whites

According to a story from Multiple Sclerosis News Today, a recent study has revealed a never-before-seen difference in multiple sclerosis patients of different racial backgrounds. The research found that people…

Continue Reading Study Reveals a Key Difference Between People of Color with Multiple Sclerosis and Whites